Go Pro
NASDAQ:AGEN

Agenus Q3 2025 Earnings Report

Agenus logo
$8.50 +0.10 (+1.19%)
Closing price 04:00 PM Eastern
Extended Trading
$8.44 -0.05 (-0.65%)
As of 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agenus EPS Results

Actual EPS
$1.94
Consensus EPS
$2.63
Beat/Miss
Missed by -$0.69
One Year Ago EPS
N/A

Agenus Revenue Results

Actual Revenue
$30.24 million
Expected Revenue
$80.39 million
Beat/Miss
Missed by -$50.15 million
YoY Revenue Growth
N/A

Agenus Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Monday, November 10, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Agenus' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 3, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Agenus Earnings Headlines

Agenus Inc. (NASDAQ:AGEN) Given Average Rating of "Hold" by Analysts
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel
Chardan Capital Initiates Coverage on Agenus (NASDAQ:AGEN)
Chardan Initiates Agenus at Buy With $40 Price Target
Longeveron (NASDAQ:LGVN) and Agenus (NASDAQ:AGEN) Head to Head Survey
See More Agenus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Agenus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Agenus and other key companies, straight to your email.

About Agenus

Agenus (NASDAQ:AGEN) (NASDAQ: AGEN) is a biotechnology company focused on developing immunotherapies for the treatment of cancer. Its research programs are designed to activate and direct the immune system against tumors, with an emphasis on therapies that may address immune resistance and improve responses in difficult-to-treat cancers.

The company’s pipeline has included checkpoint inhibitors, cancer vaccines, immune-stimulating adjuvants, bispecific antibodies and other antibody-based therapies. Among its investigational programs are botensilimab, an Fc-enhanced CTLA-4 antibody, and balstilimab, a PD-1 inhibitor. Agenus has evaluated these and other candidates in clinical studies across multiple cancer types, including colorectal cancer and other solid tumors. These products remain investigational unless approved by applicable regulatory authorities.

Agenus was founded in 1994 and was formerly known as Antigenics before adopting the Agenus name in 2011. The company is headquartered in Lexington, Massachusetts, and conducts research and clinical development through operations and collaborations in the United States and internationally. Garo Armen, one of the company’s founders, serves as chairman and chief executive officer.

View Agenus Profile